Sarepta Slumps After FDA Says Duchenne Drug Efficacy UnprovenBy
Stock down as much as 60%, biggest drop since November 2013
Effects `too small and variable, FDA staff says in report
Sarepta Therapeutics Inc.sank as much as 60 percent, the most since November 2013, after the U.S. Food and Drug Administration staff said its experimental drug aimed at treating Duchenne muscular dystrophy hasn’t been proven to work in clinical trials.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.
- Smartphones Are Killing Americans, But Nobody’s Counting
- Why a Pub in the Middle of Nowhere Was Named the World’s Best Restaurant
- Gulf Coast Oil Spill May Be Largest Since 2010 BP Disaster
- Marc Faber Asked to Leave Sprott Board After Racist Report
- Airbus Snaps Up Bombardier Jet in New Challenge to Boeing